Identifying the regional substrates predictive of Alzheimer's disease progression through a convolutional neural network model and occlusion

Progressive brain atrophy is a key neuropathological hallmark of Alzheimer's disease (AD) dementia. However, atrophy patterns along the progression of AD dementia are diffuse and variable and are often missed by univariate methods. Consequently, identifying the major regional atrophy patterns u...

Full description

Saved in:
Bibliographic Details
Published inHuman brain mapping Vol. 43; no. 18; pp. 5509 - 5519
Main Authors Kwak, Kichang, Stanford, William, Dayan, Eran
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 15.12.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Progressive brain atrophy is a key neuropathological hallmark of Alzheimer's disease (AD) dementia. However, atrophy patterns along the progression of AD dementia are diffuse and variable and are often missed by univariate methods. Consequently, identifying the major regional atrophy patterns underlying AD dementia progression is challenging. In the current study, we propose a method that evaluates the degree to which specific regional atrophy patterns are predictive of AD dementia progression, while holding all other atrophy changes constant using a total sample of 334 subjects. We first trained a dense convolutional neural network model to differentiate individuals with mild cognitive impairment (MCI) who progress to AD dementia versus those with a stable MCI diagnosis. Then, we retested the model multiple times, each time occluding different regions of interest (ROIs) from the model's testing set's input. We also validated this approach by occluding ROIs based on Braak's staging scheme. We found that the hippocampus, fusiform, and inferior temporal gyri were the strongest predictors of AD dementia progression, in agreement with established staging models. We also found that occlusion of limbic ROIs defined according to Braak stage III had the largest impact on the performance of the model. Our predictive model reveals the major regional patterns of atrophy predictive of AD dementia progression. These results highlight the potential for early diagnosis and stratification of individuals with prodromal AD dementia based on patterns of cortical atrophy, prior to interventional clinical trials. Progressive brain atrophy is a key neuropathological hallmark of Alzheimer's disease (AD). However, atrophy patterns along the progression of AD are diffuse and variable and are often missed by univariate methods. Here, we propose a method based upon deep learning that evaluates the degree to which specific regional atrophy patterns are predictive of AD progression, while holding all other atrophy changes constant. Our results show that atrophy in the hippocampus, fusiform, and inferior temporal gyri was the strongest predictor of AD progression.
Bibliography:Funding information
As such, the investigators within the ADNI contributed to the design and implementation of the ADNI and/or provided data but did not participate in analysis or writing of this article. A complete listing of ADNI investigators can be found at
http://adni.loni.usc.edu
http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf
University of Southern California; Northern California Institute for Research and Education; Foundation for the National Institutes of Health; Canadian Institutes of Health Research; Transition Therapeutics; Takeda Pharmaceutical Company; Piramal Imaging; Servier; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Neurotrack Technologies; NeuroRx Research; Meso Scale Diagnostics, LLC.; Merck & Co., Inc; Lundbeck; Lumosity; Johnson & Johnson Pharmaceutical Research & Development LLC; Janssen Alzheimer Immunotherapy Research & Development, LLC.; IXICO Ltd.; GE Healthcare; Fujirebio; Genentech, Inc.; F. Hoffmann‐La Roche Ltd; EuroImmun; Eli Lilly and Company; Elan Pharmaceuticals, Inc.; Eisai Inc.; Cogstate; CereSpir, Inc.; Bristol‐Myers Squibb Company; Biogen; BioClinica, Inc; Araclon Biotech; Alzheimer's Drug Discovery Foundation; Alzheimer's Association; AbbVie; National Institute of Biomedical Imaging and Bioengineering; National Institute on Aging; Department of Defense, Grant/Award Number: W81XWH‐12‐2‐0012; National Institutes of Health, Grant/Award Number: U01 AG024904; Alzheimer's Disease Neuroimaging Initiative
Data used in the preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database
.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Funding information University of Southern California; Northern California Institute for Research and Education; Foundation for the National Institutes of Health; Canadian Institutes of Health Research; Transition Therapeutics; Takeda Pharmaceutical Company; Piramal Imaging; Servier; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Neurotrack Technologies; NeuroRx Research; Meso Scale Diagnostics, LLC.; Merck & Co., Inc; Lundbeck; Lumosity; Johnson & Johnson Pharmaceutical Research & Development LLC; Janssen Alzheimer Immunotherapy Research & Development, LLC.; IXICO Ltd.; GE Healthcare; Fujirebio; Genentech, Inc.; F. Hoffmann‐La Roche Ltd; EuroImmun; Eli Lilly and Company; Elan Pharmaceuticals, Inc.; Eisai Inc.; Cogstate; CereSpir, Inc.; Bristol‐Myers Squibb Company; Biogen; BioClinica, Inc; Araclon Biotech; Alzheimer's Drug Discovery Foundation; Alzheimer's Association; AbbVie; National Institute of Biomedical Imaging and Bioengineering; National Institute on Aging; Department of Defense, Grant/Award Number: W81XWH‐12‐2‐0012; National Institutes of Health, Grant/Award Number: U01 AG024904; Alzheimer's Disease Neuroimaging Initiative
Data used in the preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (http://adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of the ADNI and/or provided data but did not participate in analysis or writing of this article. A complete listing of ADNI investigators can be found at http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.
ISSN:1065-9471
1097-0193
1097-0193
DOI:10.1002/hbm.26026